Form D · Biotechnology
Monod Bio, Inc.
Seattle, WA · CIK 0001897839
Offering snapshot reported Jun 24, 2022 · SEC filing
- Reported sold
- $24.2M Offering amount: $26.3M
- Investors reported
- 31 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 10, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 24, 2022 | Initial | $24,213,376 | No comparison | 31 | SEC filing |
| Dec 14, 2021 | Initial | $6,000,000 | No comparison | 27 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-450212
Source: Form D, filed Jun 24, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Berta Melina Cimler | Director |
| Dave Johnson | Director |
| Alfredo Quijano Rubio | Executive |
| Alfredo Quijano Rubio | Executive |
| David A Shoultz | Director, Executive |
| Daniel Adriano Silva Manzano | Director, Executive |
| Karan Takhar | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Fluke Hall Uw 4000 Mason Road
Seattle, WA, 98105
Seattle, WA, 98105